Future Science Group
Browse
Supplementary_Appendix_Updated.pdf (756.71 kB)

Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study Supplementary Appendix

Download (756.71 kB)
dataset
posted on 2023-05-15, 13:21 authored by John Mascarenhas, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Richard Perry, Ali McBride

Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study Supplementary Appendix 

Funding

This study was funded by Bristol Myers Squibb. J Mascarenhas reports consultancy fees from AbbVie, Bristol Myers Squibb, CTI BioPharma, Galecto, GSK, Incyte, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, PharmaEssentia, Roche and Sierra Oncology; payment or honoraria from AbbVie, Bristol Myers Squibb and MorphoSys; participation on a data safety monitoring board or advisory board for Galecto; and research funding from AbbVie, Bristol Myers Squibb, CTI BioPharma, Incyte, Kartos Therapeutics, Novartis and PharmaEssentia. H Nguyen and A Saunders report employment with and stock ownership in Bristol Myers Squibb. L Oliver and H Tomkinson were employees of Adelphi Values PROVE when this research was conducted. R Perry reports employment with Adelphi Values PROVE. A McBride reports employment with Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing and editorial support were provided by Niamh Burke, PhD, of Excerpta Medica, funded by Bristol Myers Squibb.

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC